Satralizumab

Summary

Satralizumab (CHEMBL3833307) is an approved antibody (ATC L04AC19); indicated across 7 conditions including neuromyelitis optica and immune system disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: L04AC19
• Indications: 7 conditions
• Clinical trials: 14

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3833307
Name	Satralizumab
Type	Antibody
Max phase	4
ATC	L04AC19

Also known as: Enspryng, RG6168, SA-237, SA237, Sapelizumab, Satralizumab, Satralizumab mwge, Satralizumab-mwge, SATRALIZUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	Interleukin-6 receptor	Binding	8.85

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neuromyelitis optica	4	MONDO:0019100	EFO:0004256
immune system disorder	4	MONDO:0005046	EFO:0000540
myasthenia gravis	3	MONDO:0009688	EFO:0004991
Japanese encephalitis	3	MONDO:0019209	EFO:0007332
pulmonary arterial hypertension	2	MONDO:0015924	EFO:0001361
Duchenne muscular dystrophy	2	MONDO:0010679	MONDO:0010679

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
PHASE3	9
PHASE4	2
PHASE2	1
EARLY_PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07010302	PHASE4	NOT_YET_RECRUITING	Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD
NCT05269667	PHASE4	TERMINATED	A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention
NCT05199688	PHASE3	RECRUITING	A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT05271409	PHASE3	RECRUITING	A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
NCT05503264	PHASE3	RECRUITING	A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
NCT05987423	PHASE3	ACTIVE_NOT_RECRUITING	Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
NCT06106828	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
NCT02028884	PHASE3	COMPLETED	Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
NCT02073279	PHASE3	COMPLETED	Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT04660539	PHASE3	COMPLETED	A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT04963270	PHASE3	TERMINATED	A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
NCT06450639	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
NCT05727657	EARLY_PHASE1	WITHDRAWN	Satralizumab in Aneurysmal Subarachnoid Hemorrhage
NCT06829524	Not specified	NOT_YET_RECRUITING	HANDLE-a Real World Study on Satralizumab in NMOSD

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).